Cargando…
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome. METHODS: A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed between 1992 and 2011. The IPSS and L...
Autores principales: | Benites, Bruno Deltreggia, Lima, Carolina Silva Costa, Lorand-Metze, Irene, Delamain, Marcia Torresan, Oliveira, Gislaine Borba, de Almeida, Daiane, de Souza, Carmino Antonio, Vassallo, Jose, Pagnano, Katia Borgia Barbosa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611898/ https://www.ncbi.nlm.nih.gov/pubmed/23644853 http://dx.doi.org/10.6061/clinics/2013(03)OA09 |
Ejemplares similares
-
Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center
por: Moura, Ariella Cássia de, et al.
Publicado: (2019) -
Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up
por: PAGNANO, KATIA BORGIA BARBOSA, et al.
Publicado: (2016) -
Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol
por: Pagnano, Kátia B. Barbosa, et al.
Publicado: (2010) -
Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase
por: Moura, Muriel Silva, et al.
Publicado: (2019) -
Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response
por: Machado, Melissa Pereira, et al.
Publicado: (2011)